Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
122%(11 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_3
7
64%
Ph phase_2
4
36%

Phase Distribution

0

Early Stage

4

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
4(36.4%)
Phase 3Large-scale testing
7(63.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
81.8%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (36.4%)
Phase 37 (63.6%)

Trials by Status

terminated218%
completed982%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

NCT03864614
completedphase_3

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

NCT04442490
completedphase_3

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
completedphase_2

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

NCT03692910
completedphase_3

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

NCT04442503
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03864614Phase 3

A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)

Completed
NCT04442490Phase 3

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Completed
NCT04476030Phase 3

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Completed
NCT03692910Phase 2

A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode

Completed
NCT04442503Phase 3

A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Completed
NCT03000569Phase 2

A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease

Completed
NCT04007367Phase 3

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Terminated
NCT03672175Phase 3

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

Completed
NCT03771664Phase 3

A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia

Terminated
NCT03000530Phase 2

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Completed
NCT02978781Phase 2

A Study to Evaluate SAGE-217 in Participants With Essential Tremor

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11